Friday, June 3, 2022
1:00 Opening Ceremony– Richard Hillman, President of IANS
1:15 Introduction by Farrah Fawcett Foundation: Alana Stewart, CEO of the Farrah Fawcett Foundation
Farrah Fawcett Foundation Keynote Address – Treatment of anal cancer, potential use of biological markers and future directions – Karen-Lise Garm Spindler
2:00 Oral Abstract Session - Epidemiology and natural history (non-CME) - Session Chair
Gary Clifford |
Predictors of anal high-grade squamous intraepithelial lesions after two years of cytological and histological follow-up in men who have sex with men living with HIV |
Sameer V. Gopalani |
Incidence trends for HPV-associated anal squamous cell carcinoma in the United States, 1999-2018. |
Ramon P. van der Zee |
Recent trends in incidence and risk factors of anal cancer in HIV-infected patients in the Netherlands: improved cancer survival in patients diagnosed with anal cancer while in screening |
2:35 Novel host determinants of HPV-related diseases can inform new treatment strategies -
Andrea Lisco
3:15 Coffee Break
3:30 Quick-Hit Abstract Session - Screening and diagnostics and Epidemiology/natural history (non-CME)– Session Chairs
Danielle R. L. Brogden |
The incidences and disease patterns of HPV related cancers in England. |
Ben Cardenas |
Evaluating the cascade of care for anal cancer screening within a Ryan White HIV/AIDS program clinic |
Megan A. Clarke |
The Anal Cancer Etiology and Screening (ACES) Study: Design and Baseline Characteristics |
Richard Gilson |
Screening and early detection to prevent anal cancer (SEPAC): protocol and progress report |
3:55 What is happening with anal cancer precursors in low/middle income countries - Valeria Fink
4:30 HPV vaccination among gay, bisexual, and other men who have sex with men –
Ann Burchell
5:00 Leveraging existing surveillance systems and creating new ones for anal cancer: Perspectives from the CDC
Mona Saraiya
5:15 Research Review Panel: Large cohort/treatment studies from around the world
Andrew Grulich, Mary Poynten, and Tamzin Cuming
6:15 - 7:15 Opening Reception & Poster Session
8:00 Working IANS Breakfast
9:00 Multizonal disease
Michelle Khan and Bernadette Cracchiolo
Session Chair
9:30 ANCHOR Keynote Address: Results of the ANCHOR Study – Joel Palefsky
10:30 Anal HPV and cancer epidemiology – what’s new – Gary Clifford
10:55 Coffee Break
11:10 Oral Abstracts Session – Screening and Diagnostics (non-CME)
Camryn Cohen |
Automated evaluation of p16/Ki-67 dual stain cytology improves detection of anal precancer in MSM living with HIV |
Michael Gaisa |
Genital and anal cytology-HPV cotesting results and prediction nomogram for anal high-risk HPC infection in women living with HIV |
Fernando Dias Gonçalves Lima |
Host cell DNA methylation analysis on minimally invasive anal swabs for the detection of HGAIN and anal cancer in HIV+ MSM |
Keith Sigel |
Anal Dysplasia Screening in People with HIV Younger than 35 |
12:00 Lunch on own & Poster Session
1:20 Quick-Hit Abstract Session (non-CME) – Session Chairs
Jonathan Baker |
Experience of implementing an HIV preexposure prophylaxis (PrEP) program into an anal dysplasia-focused office. |
Eugenio Nelson Cavallari |
Reduction of Intraepithelial NK cells Characterizes Anal Dysplasia of Any Grade in HIV+/HPV+ Subjects |
Amit Gupta |
Awareness of outpatient anal cancer screening among men who have sex with men living with HIV in Canada: The HPV Screening and Vaccine Evaluation (HPV-SAVE) Study |
Hillary Johnson |
The efficacy of topical Dihydroartemisinin to treat anal dysplasia in mice |
Hamish Urquhart |
Anal Squamous Cell Carcinoma (ASCC) treated by excision alone results in higher rates of HSIL, and high-risk HPV genotypes when compared to chemoradiotherapy |
1:55 IANS Guidelines Update - Naomi Jay, Elizabeth Stier, Megan Clarke and
Gary Clifford
2:35 Inside the Guidelines Development Process – Laura Bachmann
2:50 Oral Abstract Session – Screening and Diagnostics (non-CME) - Session Chairs
Tamzin Cuming |
The value of high resolution anoscopy (HRA) in the early diagnosis of anal cancer in a high-risk cohort |
Yuxin Liu |
HPV Testing Differentiates Metastatic Anal Cancer in the Lung from Primary Lung Cancer |
Nick Matolka |
Performance of 2 different High-Risk HPV assays to predict high-grade squamous intraepithelial lesions (HSIL) on high-resolution anoscopy (HRA). |
3:30 Coffee Break
3:45 Natural history and biomarkers of HPV-related cancers: A comparison between anus and cervix –
Nicolas Wentzensen
4:15 ANCHOR Panel Review
Joel Palefsky, Gary Clifford, Andrew Grulich
Chair: Tamzin Cuming
5:00 End of session
6:00 “A Night at the Opera” Optional Social Activity
8:00 Breakfast/IANS Membership Meeting (IANS Members only)
9:00 Oral Abstract Session (non-CME) – Session Chair
Naomi Jay |
Developing Remote High Resolution Anoscopy Training |
Helle Kiellberg Larsen |
Risk of anal human papillomavirus infection in kidney transplant recipients compared with immunocompetent controls |
Danielle R. L. Brogden |
Is local excision alone for early Anal Squamous Cell Carcinoma (ASCC) efficacious in people living with HIV (PLWH)? |
9:35 Contemporary patterns in anal cancer incidence and mortality and integration into mathematical modeling to inform guidelines and clinical practice – Ashish Deshmukh
10:15 Coffee Break
10:30 Patient Panel (non-CME)
Rare and Misunderstood: Ten Years Later - Narratives and Perspective on the Anal Cancer Experience with: Daun Ricci, Steven Post, Dr. Stephen Weitzman, John Kneapler and Justine Almada
Session Chair: Mary-Jo Murphy
11:30 Lunch on own
1:15 Early Anal Cancer Group – J. Michael Berry-Lawhorn
Session Chair
1:30 Expanding HRA Education and Services in the Post-ANCHOR World – Tamzin Cuming, Michelle Khan, Cristina Brickman and Richard Hillman
2:00 10 years of IANS - Joel, Palefsky, Stephen Goldstone and Naomi Jay
2:30 – 3:00 Wrap up, closing ceremony – Luis Barroso